Skip to main content

Response/Resistance to PD-1 Axis Inhibitors: Focus on the Tumor Microenvironment

Cover image for Research Topic "Response/Resistance to PD-1 Axis Inhibitors: Focus on the Tumor Microenvironment"
104kviews
Editorial20 October 2025
Editorial: Response/resistance to PD-1 axis inhibitors: focus on the tumor microenvironment

Immunotherapy has transformed the therapeutic landscape of oncology, reshaping standards of care in non-small cell lung cancer (NSCLC) (1), gastrointestinal malignancies, hepatocellular carcinoma (2), and beyond (3). Despite remarkable clinical success, durable benefit is achieved only in a subset of patients. Understanding the determinants of response and resistance, identifying rational combinations, and managing toxicity remain urgent priorities. In this Research Topic, fourteen contributions, including original research, reviews, study protocols, case reports, and methodological advances, collectively advance our knowledge of immune checkpoint regulation, tumor immune microenvironment (TIME) biology, predictive biomarkers, and innovative therapeutic strategies. Together, they provide a timely snapshot of where the field stands and where it is headed.Several papers in this collection highlight the need to move beyond the traditional binary PD-1/PD-L1 paradigm. Zhu et al. demonstrated that PD-L2 functions as an independent immune checkpoint in Microsatellite Instability-High (MSI-H) Colon Cancer , with distinct spatial localization compared to PD-L1, suggesting that dual targeting of PD-L1 and PD-L2 may augment antigen presentation and restore immune activity (4). Importantly, this raises questions about whether PD-L2 testing should be incorporated into future biomarker panels in colorectal and potentially other cancers. Complementing this, Abdala-Saleh et al. revealed that (blockade of ) PD-1 and CTLA-4 regulate a CXCL9/10-CXCR3-IFNγ positive feedback loop that potentiates effector and cytotoxic T-cell responses (5). Their findings provide a mechanistic explanation for the observation that patients with CXCL9/10 high tumors respond more favorably to immune checkpoint inhibitors (ICIs) and further suggest therapeutic potential for engineered CXCL9-or CXCL10-Fc fusion proteins. These studies in mouse melanoma models collectively argue that checkpoint biology is not static but interconnected, and that mechanistic dissection of immune crosstalk may unlock new avenues for therapeutic intervention.Xu and Shao highlighted the synergy between immune and vascular modulation, reviewing how anti-angiogenic therapy remodels tumor vasculature to enhance immune infiltration, alleviate hypoxia, and diminish immunosuppressive signaling, thereby amplifying the efficacy of ICIs (6). Such strategies already have precedent, such as in the combination of atezolizumab with bevacizumab in hepatocellular carcinoma, as well as ivonescimab, a bispecific anti-PD-1 and anti-vascular endothelial growth factor (VEGF) antibody, as a potential first-line therapy for PD-L1-positive advanced NSCLC patients (7,8). However, ongoing refinements underscore the principle that vascular normalization is not just supportive but mechanistically synergistic. Importantly, Xu and Shao's review places angiogenesis at the intersection of immune suppression, hypoxia, and therapeutic resistance, suggesting that durable benefit will require attacking multiple hallmarks of tumor biology simultaneously Click or tap here to enter text.. NSCLC remains the central arena of immunotherapy research and continues to drive both clinical advances and conceptual innovation. Yang et al. provided evidence that neoadjuvant immuno-chemotherapy in stage III NSCLC induces tertiary lymphoid structure (TLS) formation and reshapes immune composition, with increased TLS density correlating with benefit (9). This highlights TLSs as functional biomarkers, reflecting not only immune presence but also immune organization. In parallel, Wang et al. introduced the first randomized phase II trial (InTRist), testing induction therapy with anti-PD-1 toripalimab plus chemotherapy followed by chemoradiotherapy and PD-1 consolidation in patients with bulky locally advanced NSCLC, a design that seeks to overcome hypoxia-driven radio resistance and improve resectability (10). Such sequence-focused strategies may define the next frontier of multimodality treatment. Raskova Kafkova et al. synthesized current knowledge of NSCLC tumorigenesis and ICI misuse, emphasizing PI3K/AKT/mTOR signaling and highlighting nanobodies, affibodies, probodies and DARPINs as promising next-generation therapeutics (11 ). Extending beyond molecular pathways, Shimizu et al. showed that tumor Akkermansia muciniphila predicts ICI response in NSCLC patients with low PD-L1 expression, thus linking host-microbe interactions with therapeutic efficacy (12). Taniguchi et al. reported on CD38 expression in small cell lung cancer (SCLC), demonstrating its correlation with immunosuppressive markers and induction after chemo-immunotherapy, nominating CD38 as both a biomarker and potential target (13). Collectively, these studies confirm NSCLC as both a clinical driver and conceptual incubator for immunotherapy innovation.Beyond NSCLC, studies have begun to explore rarer thoracic malignancies, areas that have historically lacked therapeutic breakthroughs. Dong et al. described a remarkable case of SMARCA4-deficient undifferentiated thoracic tumor treated successfully with tislelizumab plus chemotherapy underscoring the promise of checkpoint inhibition even in genomically aggressive tumors typically considered refractory (14). Such case reports, though anecdotal, provide critical insights into the responsiveness of rare tumors and generate hypotheses for future prospective trials.Contributions in gastrointestinal and hepatic cancers highlight the breadth of immunotherapy's reach. Yang et al. presented a case of pancreatic cancer achieving stabilization with toripalimab plus surufatinib, guided by TIME analysis (15). Du et al. applied next-generation sequencing to stratify advanced hepatocellular carcinoma patients, constructing a nomogram integrating PD-L1, tumor mutational burden, TERT, and TP53, thereby providing a framework for precision immunotherapy (16). Liu et al. extended this system prospectively by reporting that opioid-free anesthesia (OFA) shifts tumor-associated macrophage polarization toward an M1 phenotype in gastric cancer patients undergoing neoadjuvant PD-1 therapy, suggesting perioperative anesthetic choice as a modulator of immune outcomes (17). Together, these reports show that gastrointestinal cancers, often characterized by immunologically "cold" microenvironments, may be rendered more responsive by thoughtful integration of systemic and supportive interventions.Methodological innovation was also represented. Azam et al. demonstrated that deep learning models trained with same-section ground truth labels outperform those trained on adjacent sections when applied to virtual staining for CD3⁺ T-cells in NSCLC, leading to more reliable prognostic stratification (18). This work highlights the critical importance of training data and establishes new benchmarks for clinically reliable artificial intelligence (AI)-driven pathology. As computational pathology becomes more deeply integrated into oncology, such advances will be critical to ensure that predictive tools translate into real-world patient benefit.Finally, the challenge of toxicity was addressed by Wang et al., who explored the potential role of Traditional Chinese Medicine (TCM) in managing checkpoint inhibitor-induced colitis. With its capacity to modulate microbiota and inflammatory signaling, traditional medicine may complement conventional immunosuppression in resource-limited or culturally distinct settings (19). When considered alongside perioperative anesthesia studies, these reports illustrate that immunotherapy outcomes depend as much on systemic and supportive interventions as on direct tumor targeting.Across these diverse studies, several unifying themes emerge. The TIME remains central: TLS formation in NSCLC, vascular normalization in digestive cancers, macrophage repolarization in gastric cancer, and microbiome-tumor interactions collectively underscore that immune contexture, not tumor-intrinsic features alone, dictates therapeutic response. Combination strategies continue to dominate the landscape, such as rational integration of PD-1 blockade with chemotherapy, tyrosine kinase inhibitors, radiotherapy, anti-VEGF agents, or even anesthesia modulation consistently produces additive or synergistic effects. Precision medicine is advancing rapidly, with biomarkers such as PD-L2, CD38, Akkermansia muciniphila, and AI-derived immune phenotypes offering new dimensions of stratification beyond PD-L1 alone. Meanwhile, checkpoint biology itself is being redefined through deeper mechanistic insights into PD-L2, CTLA-4, and CXCR3 signaling. Importantly, toxicity management is evolving in parallel, with integrative strategies, including TCM and perioperative optimization, broadening the therapeutic window.In summary, this research topic highlights the extraordinary breadth of ongoing work at the intersection of immunotherapy and TIME research. Collectively, these fourteen papers chart a course toward more precise, durable, and tolerable treatments. They emphasize that immunotherapy now extends beyond the tumor bed to encompass host-microbiome interactions, perioperative care, anesthesia management, and computational pathology pipelines. The optimal deployment of immunotherapy will thus demand a holistic framework that integrates tumor biology, systemic physiology, host-microbe dynamics, and technological innovation. Guided by these insights, the future of cancer therapy will increasingly harness the full complexity of the immune system, delivering treatments that are more precise, more effective, and more patient-centered.

2,118 views

ORIGINAL RESEARCH
8 September 2025
Tumor Akkermansia muciniphila predicts clinical response to immune checkpoint inhibitors in non-small-cell lung cancer patients with low PD-L1 expression
Takashi Shimizu, 23 more and Toshiko Yamochi

5,740 views

5 citations

ORIGINAL RESEARCH
11 December 2024
TLS and immune cell profiling: immunomodulatory effects of immunochemotherapy on tumor microenvironment in resectable stage III NSCLC
Chaopin Yang, 10 more and Jianchuan Xia

5,854 views

10 citations

REVIEW
3 December 2024
Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers
Qinlan Xuand Dong Shao
Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers
The response rates to immunotherapy vary widely depending on the type of cancer and the specific treatment used and can be disappointingly low for many solid tumors. Fortunately, due to their complementary mechanisms of action, immunotherapy and anti-angiogenic therapy have synergistic effects in cancer treatment. By normalizing the tumor vasculature, anti-angiogenic therapy can improve blood flow and oxygenation to facilitate better immune cell infiltration into the tumor and enhance the effectiveness of immunotherapy. It also reduces immunosuppressive factors and enhances immune activation, to create a more favorable environment for immune cells to attack the tumor. Their combination leverages the strengths of both therapies to enhance anti-tumor effects and improve patient outcomes. This review discusses the vasculature-immunity crosstalk in the tumor microenvironment and summarizes the latest advances in combining anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system tumors.

4,040 views

27 citations

ORIGINAL RESEARCH
2 December 2024
PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
Lvyun Zhu, 14 more and Tao Hou

4,421 views

11 citations

PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loop
ORIGINAL RESEARCH
15 October 2024
PD-1 and CTLA-4 serve as major gatekeepers for effector and cytotoxic T-cell potentiation by limiting a CXCL9/10-CXCR3-IFNγ positive feedback loop
Noor Abdala-Saleh, 10 more and Nathan Karin
CXCR3 is a chemokine receptor with three ligands: CXCL9, CXCL10 and CXCL11. We report that in addition to attracting CXCR3+ T cells to tumor sites a key role of CXCL9 and CXCL10 is in inducing a self-feeding feedback loop that accelerates effector/cytotoxic activities of both CD4+ and CD8+ T cells while downregulating immunoregulatory protein TIM3. CXCR3KO mice displayed a markedly reduced response to anti-PD-1 and anti-CTLA-4 therapy. Results from a panel of in vivo and ex vivo 3D tumor models imply that, beyond driving CD8+ T cells into T-cell exhaustion, a major role of PD-1 and CTLA-4 is in limiting the CXCR3-based self-feeding mechanism of T cell potentiation. This may explain why patients that are CXCL9/CXCL10 high tend to respond well to anti-PD-1 therapy, as opposed to patients that are CXCL9/CXCL10 low . It also suggests a therapeutic role for CXCL9-Fc or CXCL10-Fc therapy; herein we demonstrate significant anti-tumor activity in multiple murine tumor models with such agents.

5,625 views

28 citations

ORIGINAL RESEARCH
28 June 2024
Training immunophenotyping deep learning models with the same-section ground truth cell label derivation method improves virtual staining accuracy
Abu Bakr Azam, 14 more and Yiyu Cai

5,095 views

11 citations

CLINICAL TRIAL
23 September 2024
Opioid−free anesthesia attenuates perioperative immunosuppression by regulating macrophages polarization in gastric cancer patients treated with neoadjuvant PD-1 inhibitor
Wenjian Liu, 5 more and Jingdun Xie

4,516 views

12 citations

CASE REPORT
31 May 2024
Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report
Wen Dong, 13 more and Zemin Xiao

4,043 views

12 citations

REVIEW
10 April 2024
Potential application mechanism of traditional Chinese medicine in treating immune checkpoint inhibitor-induced colitis
Jing Wang, 3 more and Hongjie Xiang

5,144 views

10 citations

Non-small cell lung cancer (NSCLC) is largely promoted by a multistep tumorigenesis process involving various genetic and epigenetic alterations, which essentially contribute to the high incidence of mortality among patients with NSCLC. Clinical observations revealed that NSCLC also co-opts a multifaceted immune checkpoint dysregulation as an important driving factor in NSCLC progression and development. For example, a deregulated PI3K/AKT/mTOR pathway has been noticed in 50-70% of NSCLC cases, primarily modulated by mutations in key oncogenes such as ALK, EGFR, KRAS, and others. Additionally, genetic association studies containing patient-specific factors and local reimbursement criteria expose/reveal mutations in EGFR/ALK/ROS/BRAF/KRAS/PD-L1 proteins to determine the suitability of available immunotherapy or tyrosine kinase inhibitor therapy.Thus, the expression of such checkpoints on tumors and immune cells is pivotal in understanding the therapeutic efficacy and has been extensively studied for NSCLC treatments. Therefore, this review summarizes current knowledge in NSCLC tumorigenesis, focusing on its genetic and epigenetic intricacies, immune checkpoint dysregulation, and the evolving landscape of targeted therapies. In the context of current and future therapies, we emphasize the significance of antibodies targeting PD-1/PD-L1 and CTLA-4 interactions as the primary therapeutic strategy for immune system reactivation in NSCLC. Other approaches involving the promising potential of nanobodies, probodies, affibodies, and DARPINs targeting immune checkpoints are also described; these are under active research or clinical trials to mediate immune regulation and reduce cancer progression. This comprehensive review underscores the multifaceted nature, current state and future directions of NSCLC research and treatment.

10,812 views

55 citations

BRIEF RESEARCH REPORT
12 March 2024
Role of CD38 in anti-tumor immunity of small cell lung cancer
Hirokazu Taniguchi, 5 more and Triparna Sen

5,650 views

6 citations

Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)
STUDY PROTOCOL
15 January 2024
Induction PD-1 inhibitor toripalimab plus chemotherapy followed by concurrent chemoradiotherapy and consolidation toripalimab for bulky locally advanced non-small-cell lung cancer: protocol for a randomized phase II trial (InTRist study)
Yu Wang, 13 more and Nan Bi

7,463 views

24 citations